MRAI Quote, Financials, Valuation and Earnings

ModivCare has a net margin of -58.85% compared to Marpai's net margin of -3.79%. Marpai's return on equity of -- beat ModivCare's return on equity of -206.4%.

Marpai has a consensus price target of --, signalling downside risk potential of --. On the other hand ModivCare has an analysts' consensus of -- which suggests that it could grow by 130.61%. Given that ModivCare has higher upside potential than Marpai, analysts believe ModivCare is more attractive than Marpai.

Marpai has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ModivCare has a beta of 0.535, suggesting its less volatile than the S&P 500 by 46.467%.

Marpai has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ModivCare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marpai pays -- of its earnings as a dividend. ModivCare pays out -- of its earnings as a dividend.

Marpai quarterly revenues are $7.4M, which are smaller than ModivCare quarterly revenues of $702M. Marpai's net income of -$4.3M is higher than ModivCare's net income of -$26.6M. Notably, Marpai's price-to-earnings ratio is -- while ModivCare's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marpai is 0.22x versus 0.06x for ModivCare. Usually stocks with elevated PS ratios are considered overvalued.

National Healthcare has a net margin of -58.85% compared to Marpai's net margin of 12.58%. Marpai's return on equity of -- beat National Healthcare's return on equity of 13.34%.

Marpai has a consensus price target of --, signalling downside risk potential of --. On the other hand National Healthcare has an analysts' consensus of -- which suggests that it could fall by --. Given that Marpai has higher upside potential than National Healthcare, analysts believe Marpai is more attractive than National Healthcare.

Marpai has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison National Healthcare has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.321%.

Marpai has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Healthcare offers a yield of 2.15% to investors and pays a quarterly dividend of $0.61 per share. Marpai pays -- of its earnings as a dividend. National Healthcare pays out 53.24% of its earnings as a dividend. National Healthcare's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Marpai quarterly revenues are $7.4M, which are smaller than National Healthcare quarterly revenues of $340.2M. Marpai's net income of -$4.3M is lower than National Healthcare's net income of $42.8M. Notably, Marpai's price-to-earnings ratio is -- while National Healthcare's PE ratio is 14.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marpai is 0.22x versus 1.42x for National Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

Regional Health Properties has a net margin of -58.85% compared to Marpai's net margin of -23.24%. Marpai's return on equity of -- beat Regional Health Properties's return on equity of -489.72%.

Marpai has a consensus price target of --, signalling downside risk potential of --. On the other hand Regional Health Properties has an analysts' consensus of -- which suggests that it could grow by 330.46%. Given that Regional Health Properties has higher upside potential than Marpai, analysts believe Regional Health Properties is more attractive than Marpai.

Marpai has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regional Health Properties has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.446%.

Marpai has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regional Health Properties offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marpai pays -- of its earnings as a dividend. Regional Health Properties pays out -- of its earnings as a dividend.

Marpai quarterly revenues are $7.4M, which are larger than Regional Health Properties quarterly revenues of $4.2M. Marpai's net income of -$4.3M is lower than Regional Health Properties's net income of -$982K. Notably, Marpai's price-to-earnings ratio is -- while Regional Health Properties's PE ratio is 0.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marpai is 0.22x versus 0.16x for Regional Health Properties. Usually stocks with elevated PS ratios are considered overvalued.

Talkspace has a net margin of -58.85% compared to Marpai's net margin of 3.95%. Marpai's return on equity of -- beat Talkspace's return on equity of -1.17%.

Marpai has a consensus price target of --, signalling downside risk potential of --. On the other hand Talkspace has an analysts' consensus of $4.00 which suggests that it could grow by 63.59%. Given that Talkspace has higher upside potential than Marpai, analysts believe Talkspace is more attractive than Marpai.

Marpai has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Talkspace has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Marpai has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Talkspace offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marpai pays -- of its earnings as a dividend. Talkspace pays out -- of its earnings as a dividend.

Marpai quarterly revenues are $7.4M, which are smaller than Talkspace quarterly revenues of $47.4M. Marpai's net income of -$4.3M is lower than Talkspace's net income of $1.9M. Notably, Marpai's price-to-earnings ratio is -- while Talkspace's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marpai is 0.22x versus 2.79x for Talkspace. Usually stocks with elevated PS ratios are considered overvalued.